Mineralys Therapeutics, Inc. (NASDAQ: MLYS) disclosed that Chief Executive Officer Jon Congleton sold 74,900 shares of the companys common stock on March 31, 2026, according to a Form 4 filing with the Securities and Exchange Commission.
The transactions generated $1.97 million in proceeds, executed at weighted average prices that ranged from $25.5006 to $27.0511 per share. The stock is trading at $26.97, reflecting a 14% gain over the past week.
The filing states the disposition occurred under a pre-established Rule 10b5-1 trading plan, which Congleton adopted on December 30, 2025. After the sales, Congleton directly holds 705,051 shares of Mineralys Therapeutics.
Recent operating and corporate developments
In its fourth-quarter 2025 results, Mineralys reported earnings per share of -0.4, outperforming analysts expectations of -0.94. Despite the earnings surprise, the company has attracted investor scrutiny related to rising general and administrative expenses.
On the management front, Mineralys appointed Jeffrey A. Munsie to the role of Chief Legal Officer; the filing notes his nearly 25 years of legal experience in the biopharmaceutical industry. The company is advancing its lead candidate, lorundrostat, positioning it as a potential fourth-line treatment while preparing for commercialization.
Analyst activity and valuation signals
Analysts have adjusted their outlooks in recent reports. Jefferies lowered its price target for Mineralys to $30 from $42, citing uncertainties around the companys strategy for lorundrostat. Stifel retained a Buy rating with a $52 price target, pointing to the companys commercial preparations after the Food and Drug Administrations acceptance of its New Drug Application. BofA Securities raised its price target to $51 from $46, attributing the change to updates on lorundrostats clinical development.
These analyst moves reflect differing assessments of the companies prospects and the pathway for its lead drug as it nears potential commercialization.
Investor tools and valuation context
Market traders can note the shares recent run and the mix of analyst targets as they evaluate valuation. The companys stock price movement and the insider sale were filed publicly in the Form 4 disclosure noted above.
Summary of material facts
- CEO Jon Congleton sold 74,900 shares on March 31, 2026, for $1.97 million.
- Sales executed under a Rule 10b5-1 plan adopted on December 30, 2025; Congleton now directly owns 705,051 shares.
- Q4 2025 EPS was -0.4 versus expectations of -0.94; concerns remain over higher general and administrative expenses.
- Jeffrey A. Munsie appointed Chief Legal Officer.
- Analyst price targets vary: Jefferies $30 (from $42), Stifel $52 (Buy), BofA $51 (from $46).